MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema

Francine M. Gregoire, Fang Zhang, Holly J. Clarke, Thomas A. Gustafson, Dorothy D. Sears, Svetlana Favelyukis, James Lenhard, Dennis Rentzeperis, L. Edward Clemens, Yi Mu, Brian E. Lavan

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

MBX-102/JNJ39659100 (MBX-102) is in clinical development as an oral glucose-lowering agent for the treatment of type 2 diabetes. MBX-102 is a nonthiazolidinedione (TZD) selective partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ that is differentiated from the TZDs structurally, mechanistically, preclinically and clinically. In diabetic rodent models, MBX-102 has insulin-sensitizing and glucose-lowering properties comparable to TZDs without dose-dependent increases in body weight. In vitro, in contrast with full PPAR-γ agonist treatment, MBX-102 fails to drive human and murine adipocyte differentiation and selectively modulates the expression of a subset of PPAR-γ target genes in mature adipocytes. Moreover, MBX-102 does not inhibit osteoblastogenesis of murine mesenchymal cells. Compared with full PPAR-γ agonists, MBX-102 displays differential interactions with the PPAR-γ ligand binding domain and possesses reduced ability to recruit coactivators. Interestingly, in primary mouse macrophages, MBX-102 displays enhanced antiinflammatory properties compared with other PPAR-γ or α/γ agonists, suggesting that MBX-102 has more potent transrepression activity. In summary, MBX-102 is a selective PPAR-γ modulator with weak transactivation but robust transrepression activity. MBX-102 exhibits full therapeutic activity without the classical PPAR-γ side effects and may represent the next generation insulin sensitizer.

Original languageEnglish (US)
Pages (from-to)975-988
Number of pages14
JournalMolecular Endocrinology
Volume23
Issue number7
DOIs
StatePublished - Jul 1 2009
Externally publishedYes

Fingerprint

Peroxisome Proliferator-Activated Receptors
Hypoglycemic Agents
Transcriptional Activation
Weight Gain
Edema
Ligands
Adipocytes
arhalofenate
Insulin
Glucose
Type 2 Diabetes Mellitus
Rodentia
Anti-Inflammatory Agents
Macrophages
Body Weight

ASJC Scopus subject areas

  • Molecular Biology
  • Endocrinology

Cite this

MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. / Gregoire, Francine M.; Zhang, Fang; Clarke, Holly J.; Gustafson, Thomas A.; Sears, Dorothy D.; Favelyukis, Svetlana; Lenhard, James; Rentzeperis, Dennis; Clemens, L. Edward; Mu, Yi; Lavan, Brian E.

In: Molecular Endocrinology, Vol. 23, No. 7, 01.07.2009, p. 975-988.

Research output: Contribution to journalArticle

Gregoire, Francine M. ; Zhang, Fang ; Clarke, Holly J. ; Gustafson, Thomas A. ; Sears, Dorothy D. ; Favelyukis, Svetlana ; Lenhard, James ; Rentzeperis, Dennis ; Clemens, L. Edward ; Mu, Yi ; Lavan, Brian E. / MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. In: Molecular Endocrinology. 2009 ; Vol. 23, No. 7. pp. 975-988.
@article{51f30144282f4eb091dc2bbebe385d18,
title = "MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema",
abstract = "MBX-102/JNJ39659100 (MBX-102) is in clinical development as an oral glucose-lowering agent for the treatment of type 2 diabetes. MBX-102 is a nonthiazolidinedione (TZD) selective partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ that is differentiated from the TZDs structurally, mechanistically, preclinically and clinically. In diabetic rodent models, MBX-102 has insulin-sensitizing and glucose-lowering properties comparable to TZDs without dose-dependent increases in body weight. In vitro, in contrast with full PPAR-γ agonist treatment, MBX-102 fails to drive human and murine adipocyte differentiation and selectively modulates the expression of a subset of PPAR-γ target genes in mature adipocytes. Moreover, MBX-102 does not inhibit osteoblastogenesis of murine mesenchymal cells. Compared with full PPAR-γ agonists, MBX-102 displays differential interactions with the PPAR-γ ligand binding domain and possesses reduced ability to recruit coactivators. Interestingly, in primary mouse macrophages, MBX-102 displays enhanced antiinflammatory properties compared with other PPAR-γ or α/γ agonists, suggesting that MBX-102 has more potent transrepression activity. In summary, MBX-102 is a selective PPAR-γ modulator with weak transactivation but robust transrepression activity. MBX-102 exhibits full therapeutic activity without the classical PPAR-γ side effects and may represent the next generation insulin sensitizer.",
author = "Gregoire, {Francine M.} and Fang Zhang and Clarke, {Holly J.} and Gustafson, {Thomas A.} and Sears, {Dorothy D.} and Svetlana Favelyukis and James Lenhard and Dennis Rentzeperis and Clemens, {L. Edward} and Yi Mu and Lavan, {Brian E.}",
year = "2009",
month = "7",
day = "1",
doi = "10.1210/me.2008-0473",
language = "English (US)",
volume = "23",
pages = "975--988",
journal = "Molecular Endocrinology",
issn = "0888-8809",
publisher = "The Endocrine Society",
number = "7",

}

TY - JOUR

T1 - MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema

AU - Gregoire, Francine M.

AU - Zhang, Fang

AU - Clarke, Holly J.

AU - Gustafson, Thomas A.

AU - Sears, Dorothy D.

AU - Favelyukis, Svetlana

AU - Lenhard, James

AU - Rentzeperis, Dennis

AU - Clemens, L. Edward

AU - Mu, Yi

AU - Lavan, Brian E.

PY - 2009/7/1

Y1 - 2009/7/1

N2 - MBX-102/JNJ39659100 (MBX-102) is in clinical development as an oral glucose-lowering agent for the treatment of type 2 diabetes. MBX-102 is a nonthiazolidinedione (TZD) selective partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ that is differentiated from the TZDs structurally, mechanistically, preclinically and clinically. In diabetic rodent models, MBX-102 has insulin-sensitizing and glucose-lowering properties comparable to TZDs without dose-dependent increases in body weight. In vitro, in contrast with full PPAR-γ agonist treatment, MBX-102 fails to drive human and murine adipocyte differentiation and selectively modulates the expression of a subset of PPAR-γ target genes in mature adipocytes. Moreover, MBX-102 does not inhibit osteoblastogenesis of murine mesenchymal cells. Compared with full PPAR-γ agonists, MBX-102 displays differential interactions with the PPAR-γ ligand binding domain and possesses reduced ability to recruit coactivators. Interestingly, in primary mouse macrophages, MBX-102 displays enhanced antiinflammatory properties compared with other PPAR-γ or α/γ agonists, suggesting that MBX-102 has more potent transrepression activity. In summary, MBX-102 is a selective PPAR-γ modulator with weak transactivation but robust transrepression activity. MBX-102 exhibits full therapeutic activity without the classical PPAR-γ side effects and may represent the next generation insulin sensitizer.

AB - MBX-102/JNJ39659100 (MBX-102) is in clinical development as an oral glucose-lowering agent for the treatment of type 2 diabetes. MBX-102 is a nonthiazolidinedione (TZD) selective partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ that is differentiated from the TZDs structurally, mechanistically, preclinically and clinically. In diabetic rodent models, MBX-102 has insulin-sensitizing and glucose-lowering properties comparable to TZDs without dose-dependent increases in body weight. In vitro, in contrast with full PPAR-γ agonist treatment, MBX-102 fails to drive human and murine adipocyte differentiation and selectively modulates the expression of a subset of PPAR-γ target genes in mature adipocytes. Moreover, MBX-102 does not inhibit osteoblastogenesis of murine mesenchymal cells. Compared with full PPAR-γ agonists, MBX-102 displays differential interactions with the PPAR-γ ligand binding domain and possesses reduced ability to recruit coactivators. Interestingly, in primary mouse macrophages, MBX-102 displays enhanced antiinflammatory properties compared with other PPAR-γ or α/γ agonists, suggesting that MBX-102 has more potent transrepression activity. In summary, MBX-102 is a selective PPAR-γ modulator with weak transactivation but robust transrepression activity. MBX-102 exhibits full therapeutic activity without the classical PPAR-γ side effects and may represent the next generation insulin sensitizer.

UR - http://www.scopus.com/inward/record.url?scp=67649598394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649598394&partnerID=8YFLogxK

U2 - 10.1210/me.2008-0473

DO - 10.1210/me.2008-0473

M3 - Article

C2 - 19389808

AN - SCOPUS:67649598394

VL - 23

SP - 975

EP - 988

JO - Molecular Endocrinology

JF - Molecular Endocrinology

SN - 0888-8809

IS - 7

ER -